荧光原位杂交技术动态检测评估膀胱肿瘤手术预后效果  

Dynamic monitoring interavesical epirubicin therapy for non-invasive bladder cancer using fluorescence in situ hybridization

作　　者：刘亚东[1] 卢晓明[1] 顾沈阳 周国洋[1] 王进峰[1] 尹九湖[1] 王礼平[1] 张娴娴[1] 

机构地区：[1]盐城市第三人民医院,江苏盐城224000 [2]苏北人民医院,江苏扬州251000

出　　处：《现代肿瘤医学》2016年第8期1232-1235,共4页Journal of Modern Oncology

摘　　要：目的:利用荧光原位杂交技术(fluorescent in situ hybridazation,FISH)评估膀胱肿瘤术(TURBT)预后效果。方法:选取2011年6月到2012年12月50例膀胱肿瘤病人。患者均术前排除上尿路泌尿系肿瘤,手术方式为经尿道膀胱肿瘤电切术(TURBT),术后接受规律膀胱内灌注(灌注药物为表柔比星)治疗。FISH检测的时间为TURBT术前,术后一周,术后三月,术后半年。结果:FISH检测中阳性细胞百分率随手术及术后膀胱灌注表柔比星总体呈逐渐下降趋势。其中术前与术后一周,FISH阳性细胞百分率变化具有统计学意义(P<0.001)。术后一周与术后三月FISH阳性细胞百分率比较,具有统计学意义(P<0.001)。术后三月至术后半年的FISH检测阳性细胞百分率下降不明显(P=0.148)。FISH阳性细胞百分率越高肿瘤复发机率越高,FISH阳性细胞百分率≥25%者与<25%者肿瘤复发率有统计学意义(P<0.001)。结论:手术和术后定期膀胱灌注可以明显降低术后三月的尿阳性细胞百分率。术后FISH阳性细胞百分率≥25%者的肿瘤复发率明显高于<25%的患者。Objective： We evaluated fluorescence in situ hybridization（ FISH） for assessing the response to therapy in patients with non-invasive bladder cancer receiving Epirubicin therapies. Methods： We selected 50 non-invasive bladder cancer patients form June 2011 to December 2012. We excluded the upper urinary tract carcinoma from these 50 patients. All operation methods were transurethral resection of bladder tumor（ TURBT）,after TURBT they received Epirubicin therapies in following half year. Fluorescence in situ hybridization was performed before TURBT,and at 1 week,3 months and 6 months during Epirubicin therapy with maintenance. Results： The percentage of positive cells decreased after operation and Epirubicin therapies in following half year. The percentage of positive cells by FISH between pre-operation and 1 week after TUBRT had significantly difference（ P 0. 001）,the percentage of positive cells by FISH between 1 week and 3 months also had significantly difference（ P 0. 001）. But compared with the percentage of positive cells between three months and six months after TURBT,there was no obvious difference（ P = 0. 148）. The higher percentage of positive cells leaded to higher tumor recurrence rate. There is a significant difference at the rate of tumor recurrence between ≥25% and 25%. Conclusion： TURBT and continuous regularly Epirubicin therapies for non-invasive bladder cancer may significantly decrease the percentage of positive cells following 3 months after operation. The recurrence rate of non-invasive bladder cancer with percentage of positive cells ≥25% is higher than that of 25%.

关 键 词：荧光 原位杂交技术 表柔比星 膀胱肿瘤 

分 类 号：R730.7[医药卫生—肿瘤] R737.14[医药卫生—临床医学]